Review Article
Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia
Table 4
Clinical outcome of t(4;11)(q21;q23)/MLL-AF4 positive ALL in different cooperative trials worldwide.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(a)data relative at Ph negative patients; (b)data relative at clinical outcome of all non-Ph+ high-risk patients evaluated, including t(4;11)/MLL-AF4 positive patients. OS: overall survival; DFS: disease-free survival; CCR: survival in continuous complete remission; CR: complete remission; HSCT: allogeneic hematopoietic stem cell transplantation; Ph+: Philadelphia-positive patients; MRD: minimal residual disease; CNS: central nervous system; MRC: British Medical Research Council; ECOG: Eastern Cooperative Oncology Group; GIMEMA: Gruppo Italiano Malattie EMatologiche dell’Adulto; GMALL: German Multicenter study group for treatment of adult Acute Lymphoblastic Leukemia; NILG: Northern Italy Leukemia Group; LALA: France-Belgium Group for Lymphoblastic Acute Leukemia in Adults; GRAALL: Group for Research on Adult Acute Lymphoblastic Leukemia (including the former France-Belgium Group for Lymphoblastic Acute Leukemia in Adults, the French Western-Eastern Group for Lymphoblastic Acute Leukemia, and the Swiss Group for Clinical Cancer Research); PETHEMA: Programa para el Estudio del la Terapeutica en Hemopatía Maligna; na: not available. |